摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

甲氯醛脲 | 1954-79-6

中文名称
甲氯醛脲
中文别名
——
英文名称
Mecloralurea
英文别名
N-methyl-N'-(2,2,2-trichloro-1-hydroxyethyl)urea;N-methyl-N'-(2,2,2-trichloro-1-hydroxy-ethyl)-urea;N-Methyl-N'-(2,2,2-trichlor-1-hydroxy-aethyl)-harnstoff;N-Methyl-N'-trichloraethylolharnstoff;1-methyl-3-(2,2,2-trichloro-1-hydroxyethyl)urea
甲氯醛脲化学式
CAS
1954-79-6
化学式
C4H7Cl3N2O2
mdl
MFCD00186800
分子量
221.471
InChiKey
BULMIDNYAWYAMZ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    135-140°
  • 沸点:
    351.2±42.0 °C(Predicted)
  • 密度:
    1.566±0.06 g/cm3(Predicted)
  • 溶解度:
    33.1 [ug/mL]

计算性质

  • 辛醇/水分配系数(LogP):
    0.7
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.75
  • 拓扑面积:
    61.4
  • 氢给体数:
    3
  • 氢受体数:
    2

SDS

SDS:7a7b936779dfbc2569591317637b3476
查看

反应信息

点击查看最新优质反应信息

文献信息

  • Nitric Oxide Releasing Prodrugs of Therapeutic Agents
    申请人:SATYAM Apparao
    公开号:US20110263526A1
    公开(公告)日:2011-10-27
    The present invention relates to nitric oxide releasing prodrugs of known drugs or therapeutic agents which are represented herein as compounds of formula (I) wherein the drugs or therapeutic agents contain one or more functional groups independently selected from a carboxylic acid, an amino, a hydroxyl and a sulfhydryl group. The invention also relates to processes for the preparation of the nitric oxide releasing prodrugs (the compounds of formula (I)), to pharmaceutical compositions containing them and to methods of using the prodrugs.
    本发明涉及已知药物或治疗剂的一氧化氮释放前药,其在此处表示为式(I)的化合物,其中药物或治疗剂包含一个或多个功能基团,独立地选自羧酸基、羟基和巯基。该发明还涉及制备一氧化氮释放前药(式(I)的化合物)的方法,含有它们的药物组合物以及使用这些前药的方法。
  • [EN] DEUTERATED ANALOGS OF ETIFOXINE, THEIR DERIVATIVES AND USES THEROF<br/>[FR] ANALOGUES DEUTÉRÉS D'ÉTIFOXINE, LEURS DÉRIVÉS ET LEURS UTILISATIONS
    申请人:ANVYL LLC
    公开号:WO2016154039A1
    公开(公告)日:2016-09-29
    This invention relates to deuterated analogs of etifoxine of Formula 1, solvates, prodrugs, and pharmaceutically acceptable salts thereof, as well as to methods for their preparation and use, and to pharmaceutical compositions. Briefly, this invention is generally directed to deuterated analogs of etifoxine as well as to methods for their preparation and use, and to pharmaceutical compositions containing the same.
    这项发明涉及到公式1的依托辛的代物、溶剂化合物、前药以及其药用盐,以及它们的制备和使用方法,以及药物组合物。简而言之,这项发明通常涉及到依托辛的代物,以及它们的制备和使用方法,以及含有它们的药物组合物。
  • Technology for the Preparation of Microparticles
    申请人:Malakhov Michael
    公开号:US20090098207A1
    公开(公告)日:2009-04-16
    Microspheres are produced by contacting a solution of a macromolecule or small molecule in a solvent with an antisolvent and a counterion, and chilling the solution. The microspheres are useful for preparing pharmaceuticals, nutraceuticals, cosmetic products and the like of defined dimensions.
    微球是通过将溶液中的大分子或小分子与抗溶剂和对离子接触,并冷却溶液而制备的。这些微球可用于制备具有明确定义尺寸的药物、营养保健品、化妆品等产品。
  • Reactions of N-(2,2-dichloro-1-cyanoethenyl)-N′-methyl(phenyl)ureas with aliphatic amines
    作者:S. A. Chumachenko、M. V. Kachaeva、O. V. Shablykin、E. B. Rusanov、V. S. Brovarets
    DOI:10.1134/s1070363217050164
    日期:2017.5
    fragments have been synthesized. The obtained N-(2,2-dichloro-1-cyanoethenyl)-N′-methyl(phenyl)ureas undergo intramolecular cyclization in the presence of triethylamine to form 4-(dichloromethylidene)-5-imino-1-methyl (phenyl)imidazolidin-2-ones. Reactions of N-(2,2-dichloro-1-cyanoethenyl)-N′-methylurea with aliphatic amines have afforded 4-(alkylamino)-4-(dichloromethyl)-5-imino-1-methylimidazolidin-2-ones
    已经合成了含有甲基或苯基片段的3,3-二氯丙-2-烯腈的新型衍生物。所获得的N-(2,2-二-1-氰基乙烯基)-N'-甲基(苯基)三乙胺的存在下进行分子内环化反应,形成4-(二亚甲基)-5-亚基-1-甲基(苯基)。咪唑烷基-2-酮。的反应ñ - (2,2-二-1-氰基乙烯基) - ñ '甲基与脂族胺已经得到4-(烷基基)-4-(二甲基)-5 -亚基-1-甲基咪唑烷-2-酮。
  • Compositions and methods to effect the release profile in the transdermal administration of active agents
    申请人:——
    公开号:US20020004065A1
    公开(公告)日:2002-01-10
    Compositions and methods for the transdermal delivery of active agents up to a period of seven days or more at substantially a zero-order release rate comprising a pharmaceutically acceptable adhesive matrix and a polymeric plastic material that provides a release rate regulating effect on the active agents.
    本发明涉及一种用于经皮递送活性药剂的组合物和方法,该组合物和方法能够在持续时间为七天或更长时间内以几乎零阶释放速率递送活性药剂,包括一种药学上可接受的粘合基质和一种聚合物塑料材料,该聚合物塑料材料对活性药剂具有释放速率调节作用。
查看更多